Nurix Therapeutics, Inc. Financials

Market Capitalization $1.41 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	-7.52
Forward PE	-7.18
Price to Sales TTM	$25.06
Price to Book MRQ	$3.55
Enterprise to Revenue	17.60
Enterprise to EBITDA	-5.33

Financial Reports as of Aug. 31, 2024

Financials

Fiscal Year Ends	2023-11-30
Most Recent Quarter	2024-08-31
Profit Margin	0.00%
Operating Margin	-433.83%
Return on Assets TTM	-29.46%
Return on Equity TTM	-57.96%

Income Statement

Revenue TTM	$56,424,000
Revenue per Share TTM	$0.92
Quarterly Revenue Growth	-31.80%
Gross Profit TTM	$-147,696,992
EBITDA	$-186,400,992
Net Income to Common TTM	$-176,976,000
Diluted EPS TTM	$-2.90
Quarterly Earnings Growth YoY	-31.84%

Balance Sheet

Total Cash MRQ	$448,052,000
Total Cash per Share MRQ	$6.33
Total Debt MRQ	$
Total Debt to Equity MRQ	7.20
Current Ratio MRQ	5.29
Book Value per Share MRQ	$5.62

Cash Flow

Operating Cash Flow TTM	$-97,144,000
Levered Free Cash Flow TTM	$-56,771,000

NRIX Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	70,836,304
Float Shares	57,478,684
Avg 10 Volume	746,800
Avg 30 Volume	None
Shares Short	10,793,866
Short Ratio	11.73
Short % of Shares	16.35%
% Held by Insiders	1.45%
% Held by Institutions	97.75%

Stock Price Summary

Beta	2.20
Fifty Two Week Low	$7.65
Fifty Two Week High	$29.56
Fifty Two Week Change	58.00%
Day 50 MA	$21.13
Day 200 MA	$20.48

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date